RYGklinikken ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  5.2% 7.9% 4.5% 5.5% 4.1%  
Credit score (0-100)  44 31 45 40 48  
Credit rating  BBB BB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  654 811 1,323 1,531 1,537  
EBITDA  96.4 32.3 332 192 162  
EBIT  58.9 5.3 311 189 162  
Pre-tax profit (PTP)  54.6 4.5 309.8 181.9 161.2  
Net earnings  39.7 3.2 241.1 139.0 125.6  
Pre-tax profit without non-rec. items  54.6 4.5 310 182 161  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  19.6 8.6 3.7 0.0 0.0  
Shareholders equity total  115 58.4 300 189 176  
Interest-bearing liabilities  100 10.0 30.8 45.0 76.9  
Balance sheet total (assets)  478 487 618 421 436  

Net Debt  -300 -383 -453 -225 -292  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  654 811 1,323 1,531 1,537  
Gross profit growth  -11.1% 24.0% 63.2% 15.7% 0.4%  
Employees  0 0 0 0 2  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 -778.8 -991.8 -1,338.5 -1,375.1  
Balance sheet total (assets)  478 487 618 421 436  
Balance sheet change%  -15.6% 1.8% 26.9% -31.9% 3.8%  
Added value  96.4 811.1 1,323.4 1,548.0 1,537.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -75 -54 -42 -7 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  3.0 4.0 5.0 5.0 5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  9.0% 0.7% 23.5% 12.3% 10.6%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  11.3% 1.1% 57.0% 36.3% 38.2%  
ROI %  17.7% 3.6% 156.7% 66.7% 67.2%  
ROE %  18.0% 3.7% 134.7% 56.9% 68.9%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  24.1% 12.0% 48.5% 44.9% 40.2%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -310.9% -1,186.2% -136.5% -116.8% -180.1%  
Gearing %  86.7% 17.1% 10.3% 23.8% 43.8%  
Net interest  0 0 0 0 0  
Financing costs %  4.1% 1.5% 24.0% 17.5% 3.8%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  1.2 1.1 1.9 1.8 1.7  
Current Ratio  1.2 1.1 1.9 1.8 1.7  
Cash and cash equivalent  399.6 393.1 483.5 269.6 369.0  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  63.5 30.0 290.9 183.2 169.7  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 769  
Employee expenses / employee  0 0 0 0 -688  
EBITDA / employee  0 0 0 0 81  
EBIT / employee  0 0 0 0 81  
Net earnings / employee  0 0 0 0 63